News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
750,866 Results
Type
Article (45915)
Company Profile (340)
Press Release (704593)
Multimedia
Podcasts (142)
Webinars (21)
Section
Business (213074)
Career Advice (2204)
Deals (37284)
Drug Delivery (132)
Drug Development (84820)
Employer Resources (178)
FDA (17013)
Job Trends (15701)
News (361814)
Policy (34754)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2654)
Accelerated approval (34)
Adcomms (33)
Allergies (150)
Alliances (52258)
ALS (177)
Alzheimer's disease (1714)
Antibody-drug conjugate (ADC) (345)
Approvals (17254)
Artificial intelligence (553)
Autoimmune disease (162)
Automation (39)
Bankruptcy (379)
Best Places to Work (11853)
BIOSECURE Act (22)
Biosimilars (202)
Biotechnology (196)
Bladder cancer (159)
Brain cancer (60)
Breast cancer (658)
Cancer (4981)
Cardiovascular disease (431)
Career advice (1858)
Career pathing (40)
CAR-T (294)
CDC (50)
Celiac Disease (2)
Cell therapy (779)
Cervical cancer (36)
Clinical research (72300)
Collaboration (1804)
Company closure (5)
Compensation (1188)
Complete response letters (69)
COVID-19 (2810)
CRISPR (97)
C-suite (879)
Cystic fibrosis (149)
Data (6305)
Decentralized trials (2)
Denatured (41)
Depression (139)
Diabetes (521)
Diagnostics (6811)
Digital health (49)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (268)
Drug pricing (218)
Drug shortages (34)
Duchenne muscular dystrophy (238)
Earnings (92409)
Editorial (63)
Employer branding (21)
Employer resources (158)
Events (121618)
Executive appointments (1009)
FDA (20185)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1508)
Gene editing (208)
Generative AI (49)
Gene therapy (633)
GLP-1 (1081)
Government (4909)
Grass and pollen (7)
Guidances (385)
Healthcare (19230)
HIV (60)
Huntington's disease (45)
IgA nephropathy (87)
Immunology and inflammation (280)
Immuno-oncology (62)
Indications (111)
Infectious disease (3093)
Inflammatory bowel disease (196)
Inflation Reduction Act (14)
Influenza (116)
Intellectual property (253)
Interviews (345)
IPO (17100)
IRA (58)
Job creations (4186)
Job search strategy (1564)
JPM (69)
Kidney cancer (17)
Labor market (86)
Layoffs (604)
Leadership (38)
Legal (8617)
Liver cancer (94)
Longevity (15)
Lung cancer (684)
Lymphoma (382)
Machine learning (43)
Management (62)
Manufacturing (835)
MASH (174)
Medical device (13918)
Medtech (13971)
Mergers & acquisitions (21266)
Metabolic disorders (1379)
Multiple sclerosis (167)
NASH (20)
Neurodegenerative disease (338)
Neuropsychiatric disorders (97)
Neuroscience (3000)
Neurotech (1)
NextGen: Class of 2026 (6742)
Non-profit (4595)
Now hiring (67)
Obesity (673)
Opinion (307)
Ovarian cancer (168)
Pain (218)
Pancreatic cancer (229)
Parkinson's disease (293)
Partnered (34)
Patents (510)
Patient recruitment (502)
Peanut (60)
People (61480)
Pharmaceutical (100)
Pharmacy benefit managers (33)
Phase 1 (22539)
Phase 2 (31732)
Phase 3 (23773)
Pipeline (5359)
Policy (313)
Postmarket research (2700)
Preclinical (9503)
Press Release (68)
Prostate cancer (244)
Psychedelics (51)
Radiopharmaceuticals (290)
Rare diseases (891)
Real estate (6420)
Recruiting (72)
Regulatory (25816)
Reports (52)
Research institute (2469)
Resumes & cover letters (374)
Rett syndrome (27)
RNA editing (18)
RSV (84)
Schizophrenia (158)
Series A (247)
Series B (196)
Service/supplier (14)
Sickle cell disease (100)
Special edition (26)
Spinal muscular atrophy (163)
Sponsored (42)
Startups (3839)
State (2)
Stomach cancer (19)
Supply chain (111)
Tariffs (100)
The Weekly (99)
Vaccines (1060)
Venture capital (94)
Weight loss (460)
Women's health (92)
Worklife (19)
Date
Today (19)
Last 7 days (631)
Last 30 days (2085)
Last 365 days (30695)
2026 (3555)
2025 (31115)
2024 (36186)
2023 (40966)
2022 (52148)
2021 (56703)
2020 (55139)
2019 (47872)
2018 (36190)
2017 (33606)
2016 (33231)
2015 (39088)
2014 (33052)
2013 (28153)
2012 (30208)
2011 (30908)
2010 (28935)
Location
Africa (830)
Alabama (84)
Alaska (7)
Arizona (318)
Arkansas (14)
Asia (43284)
Australia (6878)
California (11404)
Canada (3325)
China (1164)
Colorado (483)
Connecticut (481)
Delaware (342)
Europe (93102)
Florida (1721)
Georgia (356)
Hawaii (3)
Idaho (61)
Illinois (882)
India (68)
Indiana (535)
Iowa (22)
Japan (445)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1406)
Massachusetts (8217)
Michigan (328)
Minnesota (635)
Mississippi (5)
Missouri (129)
Montana (32)
Nebraska (28)
Nevada (126)
New Hampshire (78)
New Jersey (3051)
New Mexico (31)
New York (3009)
North Carolina (1522)
North Dakota (8)
Northern California (5555)
Ohio (338)
Oklahoma (22)
Oregon (47)
Pennsylvania (2304)
Puerto Rico (25)
Rhode Island (48)
South America (1199)
South Carolina (67)
South Dakota (1)
Southern California (4435)
Tennessee (177)
Texas (1768)
United States (40642)
Utah (339)
Vermont (1)
Virginia (279)
Washington D.C. (82)
Washington State (931)
West Virginia (4)
Wisconsin (115)
Wyoming (2)
750,866 Results for "ns pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
January 20, 2026
·
6 min read
Press Releases
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
November 19, 2025
·
4 min read
Press Releases
Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program
October 9, 2025
·
3 min read
Press Releases
Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
November 7, 2025
·
3 min read
Drug Development
NS Pharma Shares Preliminary Results of Viltolarsen (NS-065 / NCNP-01) Phase 3 Clinical Trial (RACER53 Study)
NS Pharma, Inc., a subsidiary of Nippon Shinyaku Co., Ltd., announced that it has received preliminary analysis results from the global Phase 3 clinical trial of NS-065/NCNP-01.
May 27, 2024
·
6 min read
Press Releases
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
February 11, 2026
·
6 min read
Pharm Country
NS Pharma, Inc. Shares New VILTEPSO® (Viltolarsen) Data at the MDA Clinical & Scientific Conference 2024
NS Pharma, Inc. (NS Pharma) is excited to announce participation in the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Orlando, Florida, March 3 – 6.
March 6, 2024
·
4 min read
Press Releases
NS Pharma Announces Strategic Alliance with Boston Children’s Hospital to Develop New Therapies for Rare Diseases
July 2, 2025
·
1 min read
Press Releases
SPARK NS and Haukeland University Hospital Announce Clinical Trial of D-Serine for Modifying Parkinson’s Disease Progression
January 21, 2026
·
4 min read
Japan
Japanese Pharmas Looking Beyond Borders for M&A to US, EU
Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.
December 10, 2025
·
7 min read
·
Dan Samorodnitsky
1 of 75,087
Next
